摘要: Multimodal approach to treatment has led the dramatically improved outcome of patients with osteosarcoma and Ewing sarcoma. However, despite intensive therapies incorporation novel agents in trials, therapeutic plateau recurrent sarcoma not yet been overcome. Cure for these remain a daunting challenge dismal survival rate after relapse best efforts. Certain clinical factors help prognosticate quality tumors. Because patient characteristics are different upon disease recurrence, vary widely.